Feedback / Questions
AiRuiKang (dalpiciclib) - Jiangsu Hengrui Pharma
ifebemtinib (IN10018) - InxMed
IN10018 in Combination With Dalpiciclib for Progressive Meningiomas
(clinicaltrials.gov)
-
Jun 18, 2026 -
P1 | N=24 | Not yet recruiting | Sponsor: Capital Medical University
New P1 trial
•
Brain Cancer • Meningioma • Oncology • Solid Tumor
http://clinicaltrials.gov/ct2/show/NCT07652762
Jun 18, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next